Medtronic Completes Acquisition of Ardian

Medtronic, Inc. MDT, today announced that it has completed the acquisition of privately-held Ardian, Inc., a developer of catheter-based therapies to treat hypertension and related conditions. Under the terms of the agreement announced on Nov. 22, 2010, the purchase price is $800 million in cash up front, plus additional cash payments equal to annual revenue growth through the end of Medtronic's fiscal year 2015. Medtronic had previously invested in Ardian and, prior to completion of the acquisition, held an 11.3 percent ownership stake in the Company. Medtronic expects to recognize a one-time gain on its ownership stake of approximately $80 million, which will be partially off-set by one-time transaction and acquisition costs in fiscal year 2011. Excluding the one-time gain, it is estimated the acquisition will be approximately $0.02 dilutive in Q4 fiscal year 2011, and between $0.05 to $0.06 dilutive in fiscal year 2012.